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Background/aim: Crimean-Congo hemorrhagic fever (CCHF) is a serious illness characterized by fever and hemorrhage. Endothelin-1
(ET-1), angiopoietin-2 (Ang-2), and endothelial cell-specific receptor tyrosine kinase (Tie-2) are believed to be important markers of
the pathogenesis, clinical course, and prognosis of the disease. The aim of this study was to determine ET-1, Ang-2, and Tie-2 levels in
adults with CCHF and investigate the associations between these markers and pathogenesis and disease course.
Materials and methods: Sixty CCHF patients were included in the study. The patients were classified according to disease severity
criteria and Ang-2, Tie-2, and ET-1 levels were compared.
Results: Mean serum ET-1 level was 36.62 ± 27.99 pg/mL in the patient group and 3.70 ± 4.71 pg/mL in the control group (P = 0.001).
Mean serum Ang-2 levels were 2511.18 ± 1018.64 pg/mL in the patient group and 3570.76 ± 209.52 pg/mL in the control group (P =
0.001). Mean serum Tie-2 levels were 7.35 ± 7.75 ng/mL in the patient group and 0.67 ± 1.26 ng/mL in the control group (P = 0.001).
Conclusion: Elevated ET-1 and Tie-2 levels were associated with more severe disease course, while Ang-2 level was negatively correlated
with severity in adult CCHF patients. ET-1, Tie-2, and Ang-2 levels are important prognostic parameters in CCHF and may contribute
significantly to treatment and follow-up.
Key words: Angiopoietin-2, endothelin-1, Crimean-Congo hemorrhagic fever, Tie-2

1. Introduction
Crimean-Congo hemorrhagic fever (CCHF) is a serious
illness that occurs each year in spring and summer in
endemic regions. It presents with fever and hemorrhage,
and in severe cases can lead to shock and death. The
coagulation and fibrinolysis that develop in CCHF manifest
clinically as petechiae, ecchymosis, mucosal hemorrhage,
and uncontrollable hemorrhage at venous puncture sites.
Monocytes, endothelial cells, and hepatocytes are the
main target cells in CCHF. Macrophage activation and
hemophagocytosis are likely pathological processes. The
resulting vascular damage induces clotting dysfunction
and increased capillary permeability, which result in
hemorrhagic tendency. Inflammatory mediators play an
important role in fatal cases [1,2].
Endothelin-1 (ET-1) is a key inflammatory mediator
in abnormal vascular tone, vascular remodeling, and
especially endothelial dysfunction [3]. Although present at

very low levels in healthy individuals, studies have shown
that ET-1 levels are high and correlated with clinical
course in patients with diseases characterized by vascular
and endothelial dysfunction such as CCHF [4].
Angiopoietin plays an important role in vascular
stabilization and is stored in the Weibel–Palade bodies,
which are exposed during endothelial damage. Four
angiopoietins have been identified (Ang-1, -2, -3, and
-4), and the most is known about Ang-1 and Ang2. Ang-2 is released after endothelial damage and
inhibits the action of Ang-1 by binding to its receptor,
endothelial cell-specific receptor tyrosine kinase (Tie2). It sensitizes the endothelium to inflammatory agents
(vascular destabilization) and facilitates VEGF-mediated
angiogenesis [5]. In a study of children with CCHF, Ang-2
and Tie-2 levels were observed to be elevated in correlation
with disease course [6]. However, these parameters have
not been analyzed in adult CCHF patients.

* Correspondence: drferhan68@hotmail.com

1192

This work is licensed under a Creative Commons Attribution 4.0 International License.

KERGET et al. / Turk J Med Sci
Therefore, this study was conducted to investigate
whether ET-1, Ang-2, and Tie-2 levels are associated with
mortality and disease course in adult CCHF patients with
significant endothelial and vascular damage.
2. Materials and methods
2.1. Patient selection
The study included 60 patients who were treated for CCHF
in the Infectious Diseases and Clinical Microbiology Unit
of the Atatürk University Hospital between March 2016
and September 2017. Fifteen healthy males and 15 females
engaged in farming in and around Erzurum were included
in the control group. Exclusion criteria for patients and
healthy volunteers included the presence of known hepatic,
renal, or pancreatic failure; gastrointestinal disease; acute
cardiovascular failure; cerebrovascular disorders and
hyperthyroidism; acute infections; pregnancy; and the use
of antiinflammatory drugs within the last month.
2.2. Study groups
The patients were divided into those with mild-moderate
disease and those with severe disease according to the
criteria defined by Swanepoel et al. and the modified
criteria recommended by Ergönül et al. [7,8], as well as the
clinical indicators of poor prognosis. Forty patients were
included in the mild-moderate group, 16 patients in the
severe group, and 4 patients in the fatal group.
2.3. CCHF diagnosis
Two blood samples of at least 2 mL each were collected
upon hospital admission from every patient with suspected
CCHF. The samples were allowed to coagulate for 30
min and then separated by centrifugation at 2000 rpm
for 5 min, and the serum was transferred to Eppendorf
tubes. One serum sample from each patient was sent by
appropriate transport methods to the Erzurum Regional
Public Health Laboratory, which is the regional reference
center, for serological and virological tests. The diagnosis
of CCHF was based on specific anti-IgM antibody and/or
polymerase chain reaction (PCR) positivity detected by
immunofluorescence assay (IFA).
2.4. Assessment of serum ET-1, Ang-2, and Tie-2 levels
Venous blood samples collected from the patient and
control groups were placed in serum tubes containing
separator gel and centrifuged at 3500 rpm for 7 min. ET1, Ang-2, and Tie-2 concentrations were analyzed using
ELISA kits according to the manufacturer’s instructions
(Elabscience, Wuhan, Hubei, China).
2.5. Statistical analysis
SPSS 20.0 (IBM Corp., Armonk, NY, USA) was used to
analyze the study data. The Kolmogorov–Smirnov test
was used to determine whether the data were normally
distributed. Demographic characteristics, physical
examination findings, and symptom frequency of the

patients were also analyzed. Intergroup comparisons
were done using a t-test for independent groups and the
Mann–Whitney U test for data that were not normally
distributed. The chi-square test was used to analyze
categorical data, and the relationships between cytokines
and other laboratory variables were investigated with
Spearman correlation analysis for data that did not
conform to normal distribution. The diagnostic value of
ET-1, Ang-2, and Tie-2 was assessed using the receiver
operating characteristic curve method and a cut-off point
was determined for ET-1. Results with P < 0.05 were
considered statistically significant.
3. Results
The patient group comprised 30 males (50%) and 30
females (50%). There were 18 males (60%) and 12 females
(40%) in the control group. The mean ages of the patient
and control groups were 48.93 ± 17.30 years and 42.27 ±
15.17 years, respectively. The differences in age and sex
distribution between the groups were nonsignificant.
Based on severity criteria, 16 (26.6%) patients were in the
severe group and 40 (66.6%) patients were in the mildmoderate group, while 4 patients (6.8%) died. Of these, 3
died due to multiple organ failure, while the other patient
developed chest pain, shortness of breath, and sudden loss
of consciousness followed by cardiopulmonary arrest. The
remaining 56 patients (93.2%) were discharged with full
recovery. Thirty-five (58.3%) patients had a history of tick
contact, while the other 25 (41.7%) patients were not aware
of any tick contact. Forty-five (75%) patients had contact
with animals, while the other 15 (25%) patients did not.
The mean incubation period among patients with known
history of tick contact was 3.45 days.
The most common symptoms were fatigue (100%),
anorexia (100%), and fever (91.7%). Twenty-one patients
(35%) exhibited hemorrhage either at admission or during
follow-up, most commonly in the form of gingival (15%)
and nasal bleeding (15%). Three patients (5%) had melena
and 5 patients (8.3%) had vaginal bleeding.
The most common findings on physical examination
were conjunctival hyperemia (98.3%), oropharyngeal
mucosal hyperemia (93.3%), and rash (93.3%).
Hemorrhage occurred in 21 patients (35%) during followup. Four patients (6.7%) developed bradycardia. One
patient developed atrial fibrillation and later died.
The patients’ laboratory results at time of admission
(Table 1) together with clinical indicators of poor prognosis
were used to classify the patients as having mild-moderate
or severe CCHF.
Mean ET-1 levels were 27.97 ± 16.21 pg/mL in mild and
43.47 ± 28.26 pg/mL in severe cases (P = 0.03). Mean Ang2 levels were 2836.06 ± 776.76 pg/mL in mild and 2173.51
± 1057.25 pg/mL in severe cases (P = 0.01). Mean Tie-2
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Table 1. Analysis of laboratory parameters of CCHF patients.
Laboratory parameters

Mean (min–max)

Sedimentation (mm/h)

16.2 ± 17.6 (2–93)

CRP (mg/L)

26 ± 30.5 (3–116)

Hemoglobin (g/dL)

13.2 ± 2.4 (5–17)

WBC (10 /µL)

2423.9 ± 1453.4 (390–8690)

Platelets (103/µL)

49,400 ± 37,465.1 (6000–141,000)

ALT (U/L)

280.2 ± 399.3 (17–2812)

AST (U/L)

713.5 ± 1644.2 (34–12090)

Creatine kinase (U/L)

898.1 ± 1396 (54–7940)

LDH(U/L)

1274 ± 1909 (238–12882)

BUN (mg/dL)

15.5 ± 9.9 (4–55)

Creatine (mg/dL)

0.9 ± 0.4 (0–3)

Glucose (mg/dL)

129.8 ± 47.9 (83–398)

PT (s)

13.8 ± 3 (10–24)

PTT (s)

40.4 ± 17.2 (20–113)

INR

1.1 ± 0.3 (1–2)

3

WBC: White blood cell count, ALT: alanine aminotransferase,
AST: aspartate aminotransferase, LDH: lactate dehydrogenase,
BUN: blood urea nitrogen, PT: prothrombin time, PTT: partial
thromboplastin time, INR: international normalized ratio.

levels were 4.54 ± 4.55 ng/mL in mild and 13.86 ± 1.26
ng/mL in severe cases (P = 0.001). Comparison of serum
ET-1, Ang-2, and Tie-2 levels of the severe patients group
and the healthy control group revealed highly significant
differences (Table 2).
Highly significant differences in median serum ET1, Ang-2, and Tie-2 values were observed between the
patient and healthy control groups (Table 3).
Evaluation of patients’ serum ET-1, Ang-2, and Tie2 levels according to mortality showed that surviving
patients had lower mean ET-1 and Tie-2 levels and higher
mean Ang-2 levels compared to deceased patients (Table
4). However, the differences could not be evaluated
statistically because the number of deceased patients was
too small to use a nonparametric test.
The patients’ serum ET-1, Ang-2, and Tie-2 levels were
compared with the following laboratory values: white
blood cell count (WBC), platelet count (PLT), aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
creatine phosphokinase (CPK), lactate dehydrogenase
(LDH), prothrombin time (PT), partial thromboplastin
time (PTT), and international normalized ratio (INR).
There was a weak but significant positive correlation
between Ang-2 and PLT, whereas significant weak negative
correlations were observed between Ang-2 and ALT, LDH,
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and PTT. ET-1 showed a weak negative correlation with
Ang-2 and a weak positive correlation with Tie-2. There
was a weak negative correlation between Tie-2 and PLT,
and a weak positive correlation between Tie-2 and LDH
(Table 5).
In terms of clinical findings, serum ET-1, Ang-2,
and Tie-2 levels were compared in patients with and
without hemorrhage and patients with and without lung
auscultation findings. Significant differences in median
Ang-2 and Tie-2 values were observed between patients
with and without hemorrhage.
4. Discussion
In this study, we determined that elevated serum ET-1 and
Tie-2 levels were associated with mortality and clinical
severity in patients with CCHF, while Ang-2 levels were
negatively correlated with mortality and clinical course.
CCHF manifests with sudden fever, weakness, diffuse
myalgia and arthralgia, headache, and sore throat. These
symptoms are sometimes accompanied by complaints of
nausea, vomiting, abdominal pain, and watery diarrhea.
Early signs may include hypotension, conjunctival
hyperemia, and blanching macular rash [7,9].
As with all viral hemorrhagic fevers (VHFs), the
most important fact known about the pathogenesis of
CCHF is that the virus primarily infects endothelial cells,
mononuclear cells, and hepatocytes, as well as many other
cell types, and proliferates to spread systemically. Increased
endothelial permeability and the resulting endothelial
damage have been implicated as the main pathogenetic
process leading to death.
Endothelial cells are among the main targets of the
CCHF virus [10,11]. Endothelial damage leads to the
activation of the intrinsic coagulation cascade, and
the activation of platelet adhesion, aggregation, and
degranulation results in hemostatic imbalance. Ultimately,
it leads to disseminated intravascular coagulation (DIC)
and diffuse hemorrhage due to excessive consumption
of coagulation factors [12]. In addition, liver function
impairment caused by the viral cytopathic effect in CCHF
results in reduced synthesis of plasma coagulation factors,
as most of these factors are synthesized in the liver [13].
During the follow-up of the 60 patients in our study,
hemorrhage associated with DIC was observed in 16
patients (26.6%), and 4 of the patients (6.8%) died due to
these hemorrhages and multiple organ failure. Although
hemorrhage is considered the primary cause of mortality
due to CCHF, multiple organ failure was observed to be
the most important cause of death in our study.
ET-1, one of the principal markers of endothelial cell
dysfunction and vascular damage, is a 21-amino-acid
vasoactive peptide that plays a role in vascular remodeling
and the pathogenesis of many diseases. ET-1 is present
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Table 2. Comparison of serum ET-1, Ang-2, and Tie-2 levels of patients and healthy control group.
Groups

ET-1 (pg/mL)

Ang-2 (pg/mL)

Tie-2 (ng/mL)

Mild-moderate patients

28 ± 16.2

2836.1 ± 776.8

4.5 ± 4.6

Severe patients

43.5 ± 28.3

2173.5 ± 1057.3

13.9 ± 1.3

Healthy controls

3.7 ± 4.7

3570.8 ± 209.5

0.7 ± 1.3

P*

0.001

0.001

0.001

P**

0.03

0.01

0.001

P*: Comparison of healthy controls and severe patients, P**: Comparison of mild-moderate and severe
patients.
Table 3. Comparison of serum ET-1, Ang-2, and Tie-2 levels of patients and healthy control
group, and patients with and without hemorrhage in CCHF.
Groups

ET-1 (pg/mL)

Ang-2 (pg/mL)

Tie-2 (ng/mL)

Patients

36.6 ± 27.9

2511.2 ± 1018.6

7.4 ± 7.8

Controls

3.7 ± 4.7

3570.8 ± 209.5

0.7 ± 1.2

P

0.001

0.001

0.001

Yes

33 ± 29.9

3005 ± 1118

10.4 ± 9.3

No

21 ± 26.5

3100 ± 943.3

3.5 ± 5.4

P

0.107

0.041

0.002

Hemorrhage

Table 4. Laboratory parameters of deceased patient and surviving patients, with analysis of
serum ET-1, Ang-2, and Tie-2 levels.
Surviving patients (n = 56)
(min–max)

Deceased patients (n = 4)
(min–max)

ET-1 (pg/mL)

32.4 (11.6–101.8)

95.6 (39.7–150.7)

Ang-2 (pg/mL)

2646.7 (46.9–3431)

613.1 (84.4–1036.8)

Tie-2 (ng/mL)

7.2 (0.2–29.4)

9.4 (2.83–26.8)

WBC (10 /µL)

2399.7 (390–8690)

2763.5 (1500–4330)

Platelets (103/µL)

51,464.3 (6000–141,000)

20,500 (16,000–31,000)

ALT (U/L)

210.8 (17–706)

1251.7 (270–2812)

AST (U/L)

412.5 (34–1975)

4927.2 (758–12,090)

Creatine kinase (U/L)

824.4 (54–7940)

1929.5 (442–4816)

LDH (U/L)

890.6 (238–3313)

6649.7 (1382–12,882)

BUN (mg/dL)

14.9 (4–55)

23.2 (10–39)

Creatine (mg/dL)

0.8 (0–3)

0.9 (0.6–1)

Glucose (mg/dL)

126.7 (83–398)

171.5 (102–265)

PT (s)

13.6 (10–23)

17 (11–24)

PTT (s)

38.7 (20–91)

64.5 (40–113)

INR

1.1 (1–2)

1.4 (1–2)

Laboratory parameters

3
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Table 5. The comparison of laboratory findings of CCHF patients for serum ET-1, Ang-2, and Tie-2 levels.
Laboratory parameters

PTT (r/p)

INR (r/p)

ET-1 (r/p)

Ang-2 (r/p)

TIE-2 (r/p)

WBC (10 /µL)

0.031/0.814

0.105/0.425

0.181/0.186

–0.057/0.666

0.069/0.602

Platelets (10 /µL)

–0.460/0.001

–0.129/0.327

–0.242/0.063

0.481/0.001

–0.281/0.029

ALT (U/L)

0.506/0.001

0.150/0.253

0.135/0.305

–0.393/0.002

0.116/0.377

AST (U/L)

0.636/0.001

0.187/0.152

0.168/0.199

–0.437/0.001

0.204/0.118

Creatine kinase (U/L)

0.532/0.001

0.312/0.015

0.03/0.820

–0.279/0.031

0.031/0.815

LDH (U/L)

0.654/0.001

0.201/0.123

0.220/0.092

–0.459/0.001

0.269/0.038

PT

0.231/0.076

0.818/0.001

–0.009/0.943

0.128/0.331

–0.125/0.343

0.446/0.001

0.166/0.206

–0.368/0.004

0.193/0.14

0.046/0.730

0.141/0.281

–0.087/0.508

–0.436/0.001

0.486/0.001

3

3

PTT
INR
ET-1
Ang-2

–0.226/0.083

WBC: White blood cell count, ALT: alanine aminotransferase, AST: aspartate aminotransferase, LDH: lactate dehydrogenase.

in several vital organs of the body and interacts with
transcription factors to stimulate expression of tumor
necrosis factor (TNF)-alpha, interleukin (IL)-1, and IL-6.
Inflammatory cytokines and angiogenic proteins are the
key mediators in the maintenance of vascular integrity.
Vascular endothelial growth factor (VEGF) and
angiopoietins (Ang) are the most important regulators
of vascular integrity, especially in VHFs. The best
known angiopoietins are Ang-1 and Ang-2. Ang-2 is
almost exclusively produced in endothelial cells and
stored in Weibel–Palade bodies, and it is released upon
the activation of the endothelium. The effect of Ang2 begins at the leukocyte adhesion step. It activates the
endothelium and promotes the inflammatory response
by increasing endothelial permeability. Thus, Ang-2
triggers the inflammatory response, impairs endothelial
balance, and renders the endothelium susceptible to
external influences. VEGF and TNF-alpha stimulate Ang2 synthesis. VEGF levels have been shown to be lower in
severe and fatal cases of CCHF [14–16]. In another study
of CCHF patients, TNF-alpha levels were lower in severe
cases [14]. These findings may explain the low Ang-2
levels in patients.
Like the Ang system, Tie-2 plays an important role
in the pathogenesis of VHFs. Ang-1 activates the Tie2 receptor when it binds, thus supporting vascular
stabilization. By preventing the adhesion of circulating
leukocytes to the endothelium, Tie-2 assumes the
dynamic barrier function of the endothelium and enables
the endothelium to remain quiet [17]. In contrast, Ang-2
is an antagonist and inactivates the Tie-2 receptor when
it binds, resulting in vascular imbalance [18]. Ang-2
acts as a Tie-2 antagonist. Therefore, if Tie-2 is high, a
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low Ang-2 level can be expected. At the same time, Tie2 also demonstrates the body’s strong defense against
endothelial impairment.
Ang-2 and Tie-2 levels were previously found to
be higher in pediatric CCHF patients compared to the
healthy group and were correlated with clinical course
and prognosis [6]. In another study, Ang-2 was shown
to be associated with vascular damage and prognosis in
patients infected with the dengue virus [19].
Although higher Ang-2 levels were reported in
severe disease in some of the aforementioned studies,
we observed lower levels in our study. There are several
possible reasons for this finding. First, the virus itself
may suppress the cellular immune response in infected
monocytes and lymphocytes. A second possibility is
that despite the expectation that early viremia will act
as an immunogen and stimulate the immune system, it
may cause immune tolerance and paralyze the immune
system. Alternatively, as Ang-2 is synthesized exclusively
by endothelial cells and severe cases have more endothelial
damage, we believe that the synthesis of Ang-2, along with
other endothelial functions, may be inadequate in these
patients.
In conclusion, elevated ET-1 and Tie-2 levels are closely
associated with poor prognosis and mortality in CCHF.
On the other hand, Ang-2 level was negatively correlated
with clinical course and mortality. ET-1, Tie-2, and Ang2 levels may provide guidance in terms of disease course
and clinical follow-up. Multiple organ failure was the main
cause of death due to CCHF in our study. More extensive
studies evaluating viral load and other constituents of the
angiopoietic system together are needed to reach more
definitive conclusions about this subject.
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